中文版 | English

在结果中检索

HFCAS OpenIR

浏览/检索结果: 共22条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib 期刊论文
BMC CANCER, 2022, 卷号: 22
作者:  Jin, Ying;  Lin, Chen;  Shi, Xun;  He, Qiong;  Yan, Junrong;  Yu, Xinmin;  Chen, Ming
收藏  |  浏览/下载：40/0  |  提交时间：2022/12/23
Clinical and molecular features  Efficacy and outcome  EGFR T790M mutation  Non-small-cell lung cancer  Osimertinib  
Clinical outcomes of lung adenocarcinoma patients harboring uncommon epidermal growth factor receptor (EGFR) mutations treated with EGFR-tyrosine kinase inhibitors (TKIs) 期刊论文
ANNALS OF PALLIATIVE MEDICINE, 2021
作者:  Si, Jinfei;  Gu, Xiaodong;  Wang, Wenxian;  Ying, Shenpeng;  Song, Zhengbo
收藏  |  浏览/下载：95/0  |  提交时间：2022/02/14
Epidermal growth factor receptor (EGFR)  uncommon mutation  compound mutation  double uncommon mutation  lung adenocarcinoma (lung AC)  
The correlation between the abundance of EGFR T790M mutation and osimertinib response in advanced non-small cell lung cancer 期刊论文
TRANSLATIONAL CANCER RESEARCH, 2021, 卷号: 10
作者:  Pan, Guoqiang;  Chen, Kaiyan;  Yu, Xiaoqing;  Sheng, Jiamin;  Fan, Yun
收藏  |  浏览/下载：47/0  |  提交时间：2021/11/01
Non-small cell lung cancer (NSCLC)  T790M abundance  droplet digital PCR (ddPCR)  next generation sequencing (NGS)  osimertinib  
Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway 期刊论文
ACTA PHARMACOLOGICA SINICA, 2020
作者:  Chen, Cheng;  Cheng, Chuan-dong;  Wu, Hong;  Wang, Zuo-wei;  Wang, Li;  Jiang, Zong-ru;  Wang, Ao-li;  Hu, Chen;  Dong, Yong-fei;  Niu, Wan-xiang;  Qi, Shuang;  Qi, Zi-ping;  Liu, Jing;  Wang, Wen-chao;  Niu, Chao-shi;  Liu, Qing-song
浏览  |  Adobe PDF(3476Kb)  |  收藏  |  浏览/下载：101/36  |  提交时间：2020/11/26
glioblastoma  osimertinib  temozolamide  MAPK-signaling pathway  MNK  eukaryotic translation initiation factor 4E  
Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation 期刊论文
ONCOGENE, 2020, 卷号: 39
作者:  Jin, Ying;  Bao, Hua;  Le, Xiuning;  Fan, Xiaojun;  Tang, Ming;  Shi, Xun;  Zhao, Jun;  Yan, Junrong;  Xu, Yang;  Quek, Kelly;  Elamin, Yasir Y.;  Zhang, Jianhua;  Futreal, P. Andrew;  Wistuba, Ignacio I.;  Heymach, John, V;  Lou, Guangyuan;  Shao, Lan;  He, Qiong;  Lin, Chen;  Wu, Xue;  Shao, Yang W.;  Wang, Xiaonan;  He, Jiachen;  Chen, Yamei;  Stebbing, Justin;  Chen, Ming;  Zhang, Jianjun;  Yu, Xinmin
收藏  |  浏览/下载：45/0  |  提交时间：2020/11/26
Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC 期刊论文
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 139, 期号: 无, 页码: 674-697
作者:  Chen, Yongfei;  Wu, Jiaxin;  Wang, Aoli;  Qi, Ziping;  Jiang, Taoshan;  Chen, Cheng;  Zou, Fengming;  Hu, Chen;  Wang, Wei;  Wu, Hong;  Hu, Zhenquan;  Wang, Wenchao;  Wang, Beilei;  Wang, Li;  Ren, Tao;  Zhang, Shanchun;  Liu, Qingsong;  Liu, Jing
浏览  |  Adobe PDF(12656Kb)  |  收藏  |  浏览/下载：21282/11467  |  提交时间：2018/08/17
Egfr  Alk  Dual Kinase Inhibitor  Non-small Cell Lung Cancer  
新型不可逆BTK激酶抑制剂的发现研究 学位论文
, 北京: 中国科学院研究生院, 2017
作者:  邓远欣
Adobe PDF(2196Kb)  |  收藏  |  浏览/下载：634/1  |  提交时间：2018/01/17
Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode 期刊论文
JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 60, 期号: 7, 页码: 2944-2962
作者:  Wang, Aoli;  Li, Xixiang;  Wu, Hong;  Zou, Fengming;  Yan, Xiao-E;  Chen, Cheng;  Hu, Chen;  Yu, Kailin;  Wang, Wenchao;  Zhao, Peng;  Wu, Jiaxin;  Qi, Ziping;  Wang, Wei;  Wang, Beilei;  Wang, Li;  Ren, Tao;  Zhang, Shanchun;  Yun, Cai-Hong;  Liu, Jing;  Liu, Qingsong
收藏  |  浏览/下载：27/0  |  提交时间：2018/07/26
Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode 期刊论文
JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 60, 期号: 7, 页码: 2944-2962
作者:  Wang, Aoli;  Li, Xixiang;  Wu, Hong;  Zou, Fengming;  Yan, Xiao-E;  Chen, Cheng;  Hu, Chen;  Yu, Kailin;  Wang, Wenchao;  Zhao, Peng;  Wu, Jiaxin;  Qi, Ziping;  Wang, Wei;  Wang, Beilei;  Wang, Li;  Ren, Tao;  Zhang, Shanchun;  Yun, Cai-Hong;  Liu, Jing;  Liu, Qingsong
收藏  |  浏览/下载：53/0  |  提交时间：2018/07/26
Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode 期刊论文
JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 60, 期号: 7, 页码: 2944-2962
作者:  Wang, Aoli;  Li, Xixiang;  Wu, Hong;  Zou, Fengming;  Yan, Xiao-E;  Chen, Cheng;  Hu, Chen;  Yu, Kailin;  Wang, Wenchao;  Zhao, Peng;  Wu, Jiaxin;  Qi, Ziping;  Wang, Wei;  Wang, Beilei;  Wang, Li;  Ren, Tao;  Zhang, Shanchun;  Yun, Cai-Hong;  Liu, Jing;  Liu, Qingsong
收藏  |  浏览/下载：35/0  |  提交时间：2018/07/26